NCT05039632: Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 40 planned
- Started
- 8 May 2023
- Primary completion
- 1 Feb 2028
- Arms
- Cohort I (NBTXR3, Abscopal, Anti PD-1 / PD-L1, Cohort II (NBTXR3, RadScopal, Anti PD-1 / PD-L1
- Results
- None posted
- 9 Sep 2021: Trial registered
- 8 May 2023: Trial started